

(56)

References Cited

FOREIGN PATENT DOCUMENTS

JP	62201573	9/1987
WO	WO90/14837 A1 *	12/1990
WO	WO 95/17209	6/1995
WO	WO9517210 A *	6/1995
WO	WO 96/15231	5/1996
WO	WO 96/33739	10/1996
WO	WO 96/37624	11/1996
WO	WO 97/37001	10/1997
WO	WO 98/15287	4/1998
WO	WO 98/16247	4/1998
WO	WO 98/40100	9/1998
WO	WO 98/56414	12/1998
WO	WO 98/57659	12/1998
WO	WO 98/57660	12/1998
WO	WO9856414 *	12/1998
WO	WO 99/11241	3/1999
WO	WO 99/27961	6/1999
WO	WO 00/15251	3/2000
WO	WO 01/80836	4/2000
WO	WO 00/60050 A2	10/2000
WO	WO 00/62800	10/2000
WO	WO 06/2800 A1	10/2000
WO	WO0060050 A1 *	10/2000
WO	WO01/04333 A1 *	1/2001
WO	WO 01/21151 A1	3/2001
WO	WO 01/21152	3/2001
WO	WO 01/21207	3/2001
WO	WO 01/22992	4/2001
WO	WO02/22992 A2 *	4/2001
WO	WO 02/32450	4/2002
WO	WO 02/32454	4/2002
WO	WO 02/097072	12/2002
WO	WO 00/15251 A2	3/2003
WO	WO 2004/058142	7/2004
WO	WO 2004/084937	10/2004
WO	WO 2004/098509	11/2004
WO	WO 2005/009462	2/2005
WO	WO 2005/107797	11/2005
WO	WO 2005/117958	12/2005
WO	WO 2006/060710	6/2006
WO	WO 2006/100109	9/2006
WO	WO 2006/100110	9/2006
WO	WO 2006/100111	9/2006
WO	WO 2007/006939 A2	1/2007
WO	WO 2007/008939 A2	1/2007
WO	WO 2008/032219	3/2008
WO	WO-2008/032219 A2	3/2008
WO	WO 2008/128939 A1	10/2008

OTHER PUBLICATIONS

- Klang et al. International Journal of Pharmaceutics 1996, vol. 132, pp. 33-44.*
- ChemBlink as www. chemolink.com. p. 1, 2010.*
- Halperin et al. Vaccine 2002, vol. 20, pp. 1240-1247.*
- Frey et al. (Vaccine 2003 vol. 21, pp. 4234-4237).*
- Palmer et al. (Virus Research, Oct. 2004, vol. 105, No. 2, pp. 183-194).*
- CenterWatch published by FDA (Faud News FDA Drug Approval copy right 1995-2016, p. 1-2), searched by 2016.*
- Bruhl et al. Vaccine, 2000, vol. 19, pp. 1149-1158.*
- Neirynck et al. (Nature Medicine 1999, vol. 5, pp. 1157-1163).*
- O kistner et al. Vaccine 1998, vol. 16, Issues 9-10, pp. 960-968.*
- Anonymous, "Entscheidende Daten der Phase-III-Studie zeigen: Der mittels Zellkultur hergestellte Grippeimpfstoff von Novartis ist gut verträglich und wirksam," Retrieved from http://www.klinikundforschung.de/news/061120_influenza.htm, Oct. 19, 2006.
- Brühl et al., "Humoral and self-mediated immunity to Viro cell-derived influenza vaccine," Vaccine, vol. 19, pp. 1149-1158, 2001.
- Cooper et al., "Safety and immunogenicity of CPG 7909 injection as an adjuvant to Flurix influenza vaccine," Vaccine, vol. 22, Nos. 22-23, pp. 3136-3143, Aug. 2004.
- Daems et al., "Anticipating crisis: Towards a pandemic flu vaccination strategy through alignment of public health and industrial policy," *Vaccine*, vol. 23, No. 50, pp. 5732-5742, Oct. 2005.
- Frey et al., "Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine on a non-adjuvanted in non-elderly adults," *Vaccines*, vol. 21, pp. 4234-4237, 2003.
- Fukuda et al., "Inactivated Influenza Vaccines," in *Vaccines*, Plotkin & Orenstein, eds., Chapters 17 and 18, 2004, pp. 339-388.
- Halperin et al., "Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children," *Vaccine*, vol. 20, Nos. 7-8, pp. 1240-1247, Jan. 2002.
- Hehme et al., "Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use," *Virus Res.*, vol. 103, Nos. 1-2, pp. 163-171, 2004.
- International Search Report dated Apr. 3, 2007 for WO 2007/052055.
- Joseph et al., "Liposomal immunostimulatory DNA sequence (ISS-ODN)," *Vaccine*, vol. 20, Nos. 27-28, pp. 3342-3354, Sep. 2002.
- Marsland et al., "Allergic airway inflammation is exacerbated during acute influenza infection and correlates with increased allergen presentation and recruitment of allergen-specific T-helper type 2 cells," *Clin. Exp. Allergy*, vol. 34, pp. 1299-1306, 2004.
- Nyerges et al., "Sensitizing activity to egg protein of an AIPO₄-adjuvanted full virus influenza vaccine," *Acta. Microbiol. Acad. Sci. Hung.*, vol. 29, pp. 245-253, 1982.
- O'Hagan et al., "Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen," *Vaccine*, vol. 20, 2728, pp. 3389-3398, Sep. 2002.
- Stephenson et al., "Boosting immunity to influenza H5N1 with M59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population," *Vaccine*, vol. 21, No. 15, pp. 1687-1693, Apr. 2003.
- Pickering et al., "Influenza virus pyrogenicity: central role of structural orientation of virion components and involvement of viral lipid and glycoproteins," *J. Gen. Virol.*, vol. 73, pp. 1345-1354, 1992.
- Pien, "Statement presented to committee on aging United States Senate," Internet article, URL: http://aging.senate.gov/_files/hr13hp.pdf, pp. 1-15, Sep. 2004.
- Weeke-Luttmann et al., "Anti-ovalbumin sensitizing ability in influenza vaccines in guinea pigs," *Dev. Biol. Stand.*, vol. 39, pp. 219-222, 1977.
- O'Hagan et al. (2004). "Novel approaches to vaccine delivery," *Pharma Res* 21(9):1519-1530.
- Plotnick et al. (2003). "The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA—A2/K^b transgenic mice," *Virol* 309:320-329.
- Podda and Del Giudice (2003). "MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile," *Exp Rev Vaccine* 2(2):197-204.
- Singh et al. (2005). "A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens," *Vaccine* 24(10):1680-1686.
- Wack et al. (2008). "Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza in mice," *Vaccine* 26:552-561.
- Yasuda et al. (2010). "Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children," *Adv Ther* 27(7):444-457.
- No Author, Fluad® Product Monograph, No. ATC: J07BB02, Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, May 8, 2013, pp. 1-27.
- Altaner et al. (1993). "Envelope glycoprotein gp51 of bovine leukemia virus is differently glycosylated in cells of various species and organ origin," *Vet Immunol Immunopathol.* 36(2):163-77.
- Gambaryan et al. (1998). "Effects of host-dependent glycosylation of hemagglutinin on receptor-binding properties on H1N1 human influenza A virus grown in MDCK cells and in embryonated eggs," *Virology*. 247(2):170-7.
- Higgins et al. (1996). "MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice," *Vaccine*, 14(6):478-84.